Xylotubercidin against herpes simplex virus type 2 in mice

Area of Science:

• Virology
• Medicinal Chemistry
• Pharmacology

Background:

• Pyrrolo[2,3-d]pyrimidine nucleosides like tubercidin, toyocamycin, and sangivamycin are known antiviral agents.
• Development of novel antiviral compounds against herpes simplex virus type 2 (HSV-2) is crucial.

Purpose of the Study:

• To evaluate the antiviral potency and selectivity of newly synthesized pyrrolo[2,3-d]pyrimidine nucleoside derivatives against HSV-2.
• To assess the efficacy of the most potent derivative, xylotubercidin, in preclinical HSV-2 infection models.

Main Methods:

• Synthesis and in vitro screening of pyrrolo[2,3-d]pyrimidine nucleoside derivatives against HSV-2.
• Topical and systemic administration of xylotubercidin in HSV-2 infected hairless mouse models.
• Comparison of xylotubercidin efficacy with acyclovir in animal models.

Main Results:

• Xylotubercidin demonstrated the highest potency and selectivity against HSV-2 in vitro compared to other derivatives.
• Topical and systemic xylotubercidin suppressed herpetic skin lesions, paralysis, and mortality in mice.
• Xylotubercidin showed superior efficacy to acyclovir, especially in systemic treatment of HSV-2 infected mice.

Conclusions:

• Xylotubercidin is a highly potent antiviral agent against HSV-2.
• Xylotubercidin exhibits significant potential for both topical and systemic therapeutic applications in HSV-2 infections.